Leukemia research最新文献

{"title":"Causal role of genetically predicted 731 immune cell phenotypes in chronic lymphatic leukemia: A bidirectional Mendelian randomization study","authors":"Suying Qian,&nbsp;Jiali Gong,&nbsp;Xiu Shen,&nbsp;Mengjie Chen,&nbsp;Yiquan Cheng,&nbsp;Jingwen Zhu,&nbsp;Mengmeng Huang,&nbsp;Zhilong Shi,&nbsp;Gangfeng Xiao,&nbsp;Keyue Hu,&nbsp;Kesang Li","doi":"10.1016/j.leukres.2024.107621","DOIUrl":"10.1016/j.leukres.2024.107621","url":null,"abstract":"<div><h3>Introduction</h3><div>The direct causal relationship between these anomalies and chronic lymphatic leukemia (CLL) remains ambiguous. This study sought to investigate the potential causal link between immune cells and CLL.</div></div><div><h3>Materials and methods</h3><div>The summary data for genome-wide association studies utilized in this research were sourced from various publicly accessible databases, including the GWAS and FinnGen databases. By amalgamating these extensive genetic resources, we applied an array of cutting-edge Mendelian randomization (MR) analytical techniques. Specifically, we employed the inverse variance weighting (IVW) method, the weighted median method, the MR-Egger method, the Cochran Q test, Leave-One-Out sensitivity analysis, and the weighted model method to rigorously evaluate the potential causal link between multiple immune cell phenotypes and CLL.</div></div><div><h3>Results</h3><div>IVW analyses consistently demonstrated significant causal associations between five groups of immune cells and CLL. These associations were observed in both forward MR analyses from immune cells to CLL, and reverse MR analyses from CLL to immune cells. The five groups of immune cells under investigation included CD14+ CD16- monocyte Absolute Count, CD4+CD8+ T cell Absolute Count, BAFF-R on IgD- CD27- B cell, HLA DR+ T cell Absolute Count, and CD4+ T cell Absolute Count. Further sensitivity analyses not only confirmed the consistency in the direction of the association but also ruled out potential heterogeneity and horizontal pleiotropy effects. This enhanced the robustness and reliability of the study findings.</div></div><div><h3>Conclusion</h3><div>This investigation discerned definitive causal links between five immune cell phenotypes and CLL, underscoring the pivotal role of immune cells in the pathogenesis of this disease.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"148 ","pages":"Article 107621"},"PeriodicalIF":2.1,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142682128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 infection in adult and paediatric recipients of allogeneic stem cell transplantation: The UK experience","authors":"Giovanna Lucchini,&nbsp;Elena Cozma,&nbsp;Aimee Jackson,&nbsp;Kimberly Gilmour,&nbsp;Rachel Protheroe,&nbsp;Keith Wilson,&nbsp;Karl Peggs,&nbsp;Victoria Potter,&nbsp;Anne Parker,&nbsp;Andy Peniket,&nbsp;Eleni Tholouli,&nbsp;Robert Wynn,&nbsp;Emma Nicholson,&nbsp;Charles Craddock,&nbsp;David I. Marks,&nbsp;Christopher Parrish,&nbsp;Shankara Paneesha,&nbsp;Oana Mirci-Danicar,&nbsp;Alexander M. Martin,&nbsp;Graham McIlroy,&nbsp;Persis J. Amrolia","doi":"10.1016/j.leukres.2024.107618","DOIUrl":"10.1016/j.leukres.2024.107618","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107618"},"PeriodicalIF":2.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic challenges and criteria application in a 70-year-old patient with oligo monocytic chronic granulomonocytic leukemia: A case report","authors":"Xiaomei Wang,&nbsp;Tao Chen","doi":"10.1016/j.leukres.2024.107616","DOIUrl":"10.1016/j.leukres.2024.107616","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107616"},"PeriodicalIF":2.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thiotepa-busulfan-fludarabine conditioning as a promising approach prior to haploidentical allogeneic hematopoietic stem cell transplantation in hematological malignancies with extramedullary involvement: Insights from a single center","authors":"Xianbo Huang ,&nbsp;Xianhui Wu ,&nbsp;Shasha Wang ,&nbsp;Yanling Ren ,&nbsp;Yu Xu ,&nbsp;Chen Mei ,&nbsp;Jie Jin ,&nbsp;Hongyan Tong ,&nbsp;Jiejing Qian","doi":"10.1016/j.leukres.2024.107617","DOIUrl":"10.1016/j.leukres.2024.107617","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107617"},"PeriodicalIF":2.1,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causes of death in patients with myelodysplastic syndrome and spliceosome mutations","authors":"Panayiotis D. Kontoyiannis ,&nbsp;Arjun S. Peddireddy ,&nbsp;Koji Sasaki,&nbsp;Kelly Chien,&nbsp;Jayastu Senapati,&nbsp;Guillermo Montalban-Bravo,&nbsp;Courtney DiNardo,&nbsp;Gautam Borthakur,&nbsp;Rashmi Kanagal-Shamanna,&nbsp;Carlos Bueso-Ramos,&nbsp;Sherry Pierce,&nbsp;Hagop Kantarjian,&nbsp;Guillermo Garcia-Manero,&nbsp;Samuel Urrutia","doi":"10.1016/j.leukres.2024.107612","DOIUrl":"10.1016/j.leukres.2024.107612","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107612"},"PeriodicalIF":2.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in the treatment of mantle cell lymphoma with BTK inhibitors","authors":"Jiwei Shen ,&nbsp;Jiawei Li ,&nbsp;Rui Yang ,&nbsp;Shuang Wu ,&nbsp;Zhimei Mu ,&nbsp;Shi Ding ,&nbsp;Xinyu Zhang ,&nbsp;Meiying Duo ,&nbsp;Ye Chen ,&nbsp;Ju Liu","doi":"10.1016/j.leukres.2024.107615","DOIUrl":"10.1016/j.leukres.2024.107615","url":null,"abstract":"<div><div>Mantle cell lymphoma (MCL) is a heterogenous disease that is one of the most challenging blood cancers due to its poor prognosis, high risk of relapse and drug resistance. Recent researches have brought significant changes in MCL patients outcomes and new clinical. Bruton's Tyrosine Kinase (BTK), a key kinase in the B-cell antigen receptor (BCR) signaling pathway, is a clinical research hot spot and plays a major role in the survival and spread of malignant B cells. The first generation of BTK inhibitors, led by ibrutinib, have shown promising results in targeted treatment. Meanwhile, several inhibitors have entered clinical studies and demonstrated outstanding therapeutic activity in clinical trials for MCL, indicating a good prospect for development. Despite these encouraging findings, the duration of response is limited, and resistance to BTK inhibitors develops in a portion of individuals. This review summarizes the pathogenesis of MCL and targeted BTK inhibitors and provides an overview of the mutations that can lead to resistance to BTK inhibitors. The purpose of this article is to review the literature describing these selective therapies and provides perspectives for their further development.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107615"},"PeriodicalIF":2.1,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of steroid-refractory acute/chronic graft versus host disease: A single-center real-world experience of ruxolitinib in combination with extracorporeal photopheresis in a high-risk population","authors":"V. Wais,&nbsp;A. Gantner,&nbsp;K. Strauss,&nbsp;A. Neagoie,&nbsp;C. Weidt,&nbsp;J. Schnell,&nbsp;H. Döhner,&nbsp;D. Bunjes,&nbsp;E. Sala","doi":"10.1016/j.leukres.2024.107611","DOIUrl":"10.1016/j.leukres.2024.107611","url":null,"abstract":"<div><div>Steroid-refractory acute and chronic graft-versus-host disease (SR-a/cGvHD) represents a potential life-threatening complication following allogeneic stem-cell transplantation (allo-SCT). The JAK1/2-inhibitor ruxolitinib and the extracorporeal photopheresis (ECP) have been shown to significantly improve the overall response rate (ORR) in this setting. However, about 30–40 % of high-risk patients do not respond to monotherapy and/or experience side effects. Considering the potential synergic mechanism of action of ruxolitinib and ECP and the good safety profile, we decided to investigate the role of a treatment strategy of ruxolitinib in combination with ECP in frail patients with high-risk SR-a/cGvHD. We conducted a retrospective single-center study comprising 47 patients who underwent allo-SCT from November 2018 to October 2023 and received treatment for SR-aGvHD (n=20) or SR-cGvHD (n=27) with ruxolitinib and ECP. In the SR-aGvHD group, 95 % of patients had a lower GI-tract involvement, with 80 % presenting with a grade III-IV SR-aGvHD. The ORR at day +28 was 65 %, with a 30 % CR rate. The 1-year overall survival (OS) for responders (PR and CR) was 33 % (95 % CI, 10 %-59 %). In the SR-cGvHD group, 55.6 % and 44.4 % had moderate and severe SR-cGvHD, respectively. The majority of patients (66.7 %) had a GI-involvement. The ORR at week 24 was 88 %, including 12 % CR and 76 % PR. The 1-year OS for responders was 76 % (95 % CI, 47 %-90 %). Our retrospective analysis shows that the treatment of ruxolitinib in combination with ECP has potential efficacy in patients with SR-a/cGvHD with a high-risk for transplantation-associated mortality.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107611"},"PeriodicalIF":2.1,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142579064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review","authors":"Ashmitha Kumar,&nbsp;Arunan Jeyakumar,&nbsp;Alfred K. Lam,&nbsp;Vinod Gopalan","doi":"10.1016/j.leukres.2024.107610","DOIUrl":"10.1016/j.leukres.2024.107610","url":null,"abstract":"<div><h3>Background</h3><div>The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).</div></div><div><h3>Aim</h3><div>This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.</div></div><div><h3>Methodology</h3><div>A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics.</div><div>The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).</div></div><div><h3>Results</h3><div>Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.</div></div><div><h3>Conclusion</h3><div>This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107610"},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology","authors":"Josefine Krüger ,&nbsp;Igor Wolfgang Blau ,&nbsp;Olga Blau ,&nbsp;Alice Bettelli ,&nbsp;Laura Rocchi ,&nbsp;Massimo Bocchi ,&nbsp;Jan Krönke ,&nbsp;Lars Bullinger ,&nbsp;Ulrich Keller ,&nbsp;Axel Nogai","doi":"10.1016/j.leukres.2024.107599","DOIUrl":"10.1016/j.leukres.2024.107599","url":null,"abstract":"<div><div>Multiple myeloma is an aggressive neoplasm of plasma cells. While numerous drugs have gained approval, the absence of established predictive markers for individual drug responses poses a challenge. In this study, we explored the microwell- and fluorescence-based Cellply CC-Array® technology for high-throughput analysis of <em>in vitro</em> drug responses as a potential predictive marker for patient treatment outcomes. Furthermore, we investigated its application for evaluating effector cell effectiveness. Mononuclear cells were isolated from the bone marrow of 22 patients, and <em>in vitro</em> drug response of primary myeloma cells was analyzed. <em>In vitro</em> responses towards melphalan, bortezomib, and dexamethasone in primary patient samples correlated with clinical response of the patients. The approach exhibited limitations in identifying sensitivity towards lenalidomide, daratumumab, and elotuzumab due to limited culturing time caused by poor myeloma viability <em>in vitro</em>. Through the analysis of cell proximity, the platform enabled the assessment of individual anti-tumor activity from NK and T cells. In summary, the CC-Array microwell technology allowed assessment of myeloma cell responses to selected drugs used in multiple myeloma therapy <em>in vitro</em>. To further validate these <em>in vitro</em> results against <em>in vivo</em> outcomes, screening a larger cohort is necessary.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107599"},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis","authors":"Susanne Isfort,&nbsp;Carlo Gambacorti-Passerini,&nbsp;Tim H. Brümmendorf,&nbsp;B. Douglas Smith,&nbsp;Simon Purcell,&nbsp;Maja Strecker,&nbsp;Huadong Zhao,&nbsp;Luke Kuttschreuter,&nbsp;Jane Apperley","doi":"10.1016/j.leukres.2024.107609","DOIUrl":"10.1016/j.leukres.2024.107609","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107609"},"PeriodicalIF":2.1,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}